Berenberg Bank Reiterates “Hold” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “hold” rating restated by research analysts at Berenberg Bank in a report issued on Thursday, MarketBeat reports. They presently have a GBX 2,000 price objective on the stock. Berenberg Bank’s target price would indicate a potential downside of 2.01% from the company’s current price.

A number of other research firms have also issued reports on GSK. Deutsche Bank Aktiengesellschaft increased their target price on GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, January 7th. Finally, Citigroup boosted their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of GBX 1,966.43.

GSK Stock Down 0.3%

Shares of GSK stock opened at GBX 2,041 on Thursday. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,282. The stock has a market cap of £81.87 billion, a price-to-earnings ratio of 14.70, a price-to-earnings-growth ratio of 1.24 and a beta of 0.32. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. The company has a fifty day moving average price of GBX 2,040.17 and a 200 day moving average price of GBX 1,831.29.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities research analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Anne Beal bought 196 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of GBX 5,179 per share, with a total value of £10,150.84. Also, insider Jonathan Symonds purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average price of GBX 1,951 per share, for a total transaction of £97,550. Insiders acquired a total of 11,447 shares of company stock valued at $24,273,097 in the last three months. 0.26% of the stock is owned by insiders.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK submitted bepirovirsen (an investigational hepatitis B therapy) to the EMA after trials met primary endpoints — a material regulatory milestone that could meaningfully lift GSK’s pipeline value if approved. GSK submits bepirovirsen for EMA review after trials hit primary endpoints
• Positive Sentiment: GSK expanded its buyback activity, repurchasing additional ordinary shares and lifting treasury holdings to about 6.27–6.28% — a shareholder-return action that reduces float and supports EPS. GSK expands share buyback, lifts treasury stake to 6.28%
• Positive Sentiment: Analyst support: Shore Capital reiterated a “Buy” on GSK, which can help sentiment among investors seeking broker-backed conviction. Shore Capital Group Reiterates “Buy” Rating for GSK (LON:GSK)
• Positive Sentiment: GSK Pakistan reported a 53% profit increase to Rs.10 billion for 2025 — stronger regional earnings that marginally support group-level cash generation and dividends. GSK Pakistan Profit Jumps 53% to Rs. 10 Billion in 2025
• Positive Sentiment: Commercial partnership: GSK allied with Shanghai Pharma to reintroduce its hepatitis B vaccine to China — expands market access in a large market. UK’s GSK Allies With Shanghai Pharma to Bring Hepatitis B Jab Back to China
• Neutral Sentiment: Investor outreach: GSK’s presentation at the Goldman Sachs Biopharma Innovation Summit may provide more color on strategy and pipeline but contains no immediate news. GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
• Neutral Sentiment: GSK received a $9M state redevelopment grant for its Lancaster County facility — supportive for local operations but immaterial to company-wide financials. GSK gets $9M state redevelopment grant for Lancaster County facility
• Negative Sentiment: Berenberg reaffirmed a “Hold” with a GBX 2,000 target — a conservative broker stance that may cap upside until more positive catalysts arrive. Broker Ratings

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.